Hong Kong One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing at HKIB. Regulatory frameworks have now been developed to support clinical trials and the rollout of advanced therapies. Jiang highlights…
Hong Kong Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom Lau and Dr Xia Jin explain the company’s origins as a spin-off from the University of Hong Kong’s AIDS Institute…
Brazil With the largest public healthcare system in the world, Latin America’s biggest pharma market, its leading regulatory body, and a huge and diverse population, Brazil is a strategic destination for both regional and global pharma. Read on for five things to watch in 2024 and beyond from this dynamic nation. …
Saudi Arabia Dr Walid Abbas Zaher highlights Saudi clinical trial Site Management Organisation (SMO) Carexso’s focus on addressing unmet needs in health economics, drug reinvestment modelling, and developing local talent. He emphasizes the importance of regional expertise and collaborations to advance R&D and envisions a robust local R&D ecosystem driven by competition…
Saudi Arabia As a part of the sweeping transformation Saudi Arabia is achieving thanks to its Vision 2030, the Kingdom is also advancing its research ambitions. With the restructuring of its regulatory framework along with its well-established network of research institutes and bolstered by the integration of electronic health records, Saudi has…
Saudi Arabia CEO of King Saud University Medical City (KSUMC), Dr Ahmad Hersi, provides an overview of the prominent hospital group and Saudi Arabia’s oldest and largest academic medical centre, offers insights into KSUMC’s collaborations with international organizations, its focus on prevention and pre-hospital care, and establishing itself as one of the…
Hong Kong Last Autumn, the Hong Kong government announced a plan to create a one-stop-shop clinical trial institute across the Greater Bay Area (GBACTI) as part of its plan to promote biomedical research, development and drug registration. Henry Yau, managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong…
UAE Long-established as the Middle East and Africa’s leading country in terms of rapid access to biomedical innovation, the UAE is looking to bolster this positioning in the coming years. Indeed, allowing innovation to flourish – including through hosting greater numbers of clinical trials in the country and protecting intellectual property…
Global The US National Institutes of Health (NIH) is the largest public investor in HIV/AIDS research globally. This means that, as Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy & Infectious Diseases (NIAID) Dr Carl Dieffenbach oversees a global HIV/AIDS research portfolio of more than…
India Siloed healthcare is no match for a malignant, insidious, and pervasive disease like cancer. Over recent decades, countries and regions across the world have discovered that – in the absence of a cure – a networked and holistic approach to cancer care is vital. In this vein and drawing from…
China Reporting from Chinese language media outlet Yaozh, based on recently issued annual financial reporting, shows the leading R&D spenders among the (predominantly mainland Chinese) biotech companies listed on the Hong Kong Stock Exchange (HKEX). Local heavyweight Beigene invested almost three times as much on R&D last year as its nearest…
UK A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in Cambridge; the GBP 17.9 million initiative to boster UK clinical trials, and Obsidian Therapeutics’ USD 160.5 million Series C funding raise.…
See our Cookie Privacy Policy Here